Axios

Moderna and Merck shares soar on mRNA cancer vaccine

Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after

Por Axios

1 minuto de lectura
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soar on mRNA cancer vaccine

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Business & Leadership

Perspectivas relacionadas